Centre Regional Lutte Contre Le Cancer
- Address
- lock Available on a paid plan
Oncology and Solid Tumor Research
At the Centre Regional Lutte Contre Le Cancer in Strasbourg, the strongest focus is on neoplasms, with many studies exploring how to improve treatment for a wide range of cancers in the Medical Oncology setting. Research is centered on testing new therapies, refining treatment combinations, and comparing approaches to help control disease and extend survival.
- Breast cancer, including HER2-positive, HER2-negative, triple-negative, and hormone receptor-positive disease
- Gastrointestinal cancers such as gastric, colorectal, biliary tract, rectal, and gastroesophageal junction cancers
- Head and neck cancers, including recurrent and metastatic squamous cell carcinoma
These trials commonly aim to improve disease control, reduce relapse risk, and identify better options for patients with advanced or high-risk cancers.
Breast Cancer Innovation
Breast cancer is a major research area at this site, covering early, locally advanced, metastatic, and treatment-resistant disease. Studies are evaluating new targeted and immunotherapy-based strategies, while others are looking at ways to safely reduce treatment intensity for patients who respond well.
- HER2-positive and HER2-amplified breast cancer
- HER2-negative and hormone receptor-positive breast cancer
- Triple-negative and metastatic breast cancer
Overall, the goal is to improve long-term outcomes, personalize care, and find more tolerable treatment paths for people living with breast cancer.
Gastrointestinal Cancer Studies
Another important theme is digestive system diseases, especially cancers of the stomach, colon, rectum, biliary tract, and gastroesophageal junction. The trials are designed to test new treatment combinations, strengthen postoperative strategies, and improve outcomes in advanced or unresectable disease.
- Gastric and gastroesophageal junction adenocarcinoma
- Colorectal and rectal cancer
- Biliary tract cancer and cholangiocarcinoma
Research here is focused on extending survival, lowering recurrence rates, and improving disease control when standard treatment is not enough.
Prostate Cancer and Molecular Imaging
The site also has a strong program in male urogenital diseases, especially advanced prostate cancer. Several studies are evaluating new radioligand, hormonal, and imaging-guided approaches to better manage metastatic disease and identify patients at higher risk of relapse.
- Metastatic castration-resistant prostate cancer
- Metastatic hormone-sensitive prostate cancer
- Localized high-risk prostate cancer with advanced imaging assessment
These trials aim to improve survival, refine treatment selection, and support more precise care through modern diagnostic tools.
Lung, Brain, and Other Neurologic Tumors
Research in respiratory tract diseases and nervous system diseases includes aggressive cancers such as non-small cell lung cancer, large-cell neuroendocrine carcinoma, glioblastoma, and low-grade glioma. The studies are testing new systemic therapies, better imaging methods, and approaches to improve control of difficult-to-treat brain and lung tumors.
- Non-small cell lung cancer and large-cell neuroendocrine carcinoma
- Glioblastoma and low-grade glioma
- Brain metastases and brain radionecrosis after radiotherapy
Work in this area is aimed at improving diagnosis, managing treatment-related complications, and finding more effective options for advanced disease.
Supportive Care, Symptoms, and Treatment Tolerance
Beyond direct cancer treatment, the site is also studying pathological conditions, signs and symptoms linked to cancer and its therapies. This includes research on neuropathy, cachexia, vasomotor symptoms, and other quality-of-life issues that can affect patients during or after treatment.
- Chemotherapy-induced peripheral neuropathy
- Cancer-associated cachexia
- Hot flashes and other endocrine therapy-related symptoms
These trials focus on easing symptoms, improving daily functioning, and making cancer care more manageable for patients.
Diagnostic and Precision Medicine Approaches
In addition to therapeutic studies, the Analytical, Diagnostic and Therapeutic Techniques and Equipment field is represented through research that improves how cancers are detected, characterized, and monitored. This includes imaging-based assessment, biomarker-driven selection, and studies using molecular information to guide treatment decisions.
- Advanced imaging for glioma characterization and prostate cancer detection
- ctDNA-guided treatment strategies in selected cancers
- Biomarker-focused studies in breast, gastric, and colorectal cancer
These efforts are intended to make diagnosis more accurate and help match patients with the most appropriate treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 103 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 101 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Regional Lutte Contre Le Cancer
lock Showing 1 of 57 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer | Curium Pet France | Phase III | Not Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 103 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 10 | Unknown | 2020-10-23 | 2026-06-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.